bioAffinity Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Pulmonary nodule detection is rising due to expanded screening, creating clinical challenges. CyPath Lung, a non-invasive sputum test, offers high sensitivity and negative predictive value, aiding risk stratification and reducing unnecessary procedures. Case studies show its value in early cancer detection and patient reassurance.
Fiscal Year 2024
-
Record sales and revenue growth in 2024 were driven by CyPath Lung, with national expansion underway and a pivotal FDA trial set for 2025. The company is leveraging strong leadership, a robust pipeline, and increased physician adoption to target further growth and profitability.
-
A novel flow cytometry-based lung cancer test demonstrated high accuracy and rapid, patient-friendly results, with strong reimbursement and recent inclusion in the Federal Supply Schedule. Expansion beyond Texas and into VA/military systems is planned, with FDA trials and new indications in development.